The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

QR Code

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Abstract Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD. Mice received chow diet and normal wat...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Divya P. Kumar, Rebecca Caffrey, Jonathon Marioneaux, Prasanna K. Santhekadur, Madhavi Bhat, Cristina Alonso, Srinivas V. Koduru, Binu Philip, Mukul R. Jain, Suresh R. Giri, Pierre Bedossa, Arun J. Sanyal
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2020
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/d45c25c827cc43f29d734da65c99d76f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Association between Equol Production Status and Nonalcoholic Steatohepatitis
par: Takemi Akahane, et autres
Publié: (2021)

The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity
par: Aniket Nikam, et autres
Publié: (2018)

Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
par: Tae Hyung Kim, et autres
Publié: (2021)

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis
par: Hongjiao Xu, et autres
Publié: (2020)

Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
par: Li-Song Zhang, et autres
Publié: (2012)

The development of nonalcoholic steatohepatitis is subjected to breeder dependent variation in guinea pigs
par: D. H. Ipsen, et autres
Publié: (2021)

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
par: Kawanaka M, et autres
Publié: (2013)

Author Correction: AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis
par: Hongjiao Xu, et autres
Publié: (2021)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
par: Alia Hadefi, et autres
Publié: (2021)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH).
par: Xuerong Wen, et autres
Publié: (2021)

CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis
par: Guangyong Sun, et autres
Publié: (2021)

The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017
par: Mimi Zhai, et autres
Publié: (2021)

Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice
par: Kook Hwan Kim, et autres
Publié: (2018)

Rat model of nonalcoholic steatohepatitis created by methionine and choline deficiency: biochemical and histological analyses
par: Seki A, et autres
Publié: (2011)

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
par: Sosale A, et autres
Publié: (2015)

β-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice.
par: Masuko Kobori, et autres
Publié: (2014)

PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings.
par: Monica Puligheddu, et autres
Publié: (2013)

Abdominal subcutaneous fat thickness and homeostasis model assessment of insulin resistance as simple predictors of nonalcoholic steatohepatitis
par: Hegazy MA, et autres
Publié: (2019)

The sex steroid precursor dehydroepiandrosterone prevents nonalcoholic steatohepatitis by activating the AMPK pathway mediated by GPR30
par: Longlong Li, et autres
Publié: (2021)

Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT PathwaySummary
par: Feixue Wang, et autres
Publié: (2022)

Effects of duodenal–jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats
par: Yu HH, et autres
Publié: (2019)

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
par: Diaz Soto MP, et autres
Publié: (2020)

The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis
par: Masakazu Hanayama, et autres
Publié: (2021)

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα
par: Ning Liang, et autres
Publié: (2019)

Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
par: Alam S, et autres
Publié: (2018)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
par: Ayza MA, et autres
Publié: (2020)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
par: Sandip Mukherjee, et autres
Publié: (2021)

Study of Cytochrome P450 2E1 and its allele Variants in Liver Injury of Nondiabetic, Nonalcoholic Steatohepatitis Obese Women
par: VARELA,NELSON M, et autres
Publié: (2008)

Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
par: Fatemeh Amin, et autres
Publié: (2021)

Anticancer Effect of Rosiglitazone, a PPAR‑γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
par: Yanqiao Wu, et autres
Publié: (2020)

A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models
par: Nadine Daou, et autres
Publié: (2021)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
par: Seko Y, et autres
Publié: (2018)

Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists.
par: Kylie R Dunning, et autres
Publié: (2014)

Peroxisome proliferator-activated receptor (PPAR) γ and PPARα agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders?
par: Juan M Zolezzi, et autres
Publié: (2013)

PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.
par: Lena Serghides, et autres
Publié: (2014)

PPARβ/δ Agonist Alleviates Diabetic Osteoporosis via Regulating M1/M2 Macrophage Polarization
par: Miao Chen, et autres
Publié: (2021)

Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
par: Eun-Hee Nah, et autres
Publié: (2021)

CLINICAL EFFICIENCY AND SAFETY OF FENOFIBRATE, A PPARα AGONIST, IN THE PATIENTS WITH DIABETESASSOCIATED OSTEOARTHRITIS: A CROSS-OVER PILOT STUDY
par: V. S. Shirinsky, et autres
Publié: (2017)

PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies
par: Silva-Abreu M, et autres
Publié: (2018)

Computational and biological evaluation of N-octadecyl-N'-propylsulfamide, a selective PPARα agonist structurally related to N-acylethanolamines.
par: Inmaculada Moreno-Santos, et autres
Publié: (2014)